COMPLETED

Cardiac Markers in Depressed Patients With Coronary Heart Disease - R01HL147862

Talk to us

Conditions

Coronary Heart DiseaseDepression

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Depression doubles the risk of death in patients with coronary heart disease (CHD), but so far, there is insufficient evidence that we can reduce the risk of death by treating depression. This study will investigate the cardiac risk markers that are associated with depression symptoms that remain despite treatment, and identify potential targets for their treatment. The results of the study will inform the development of more effective interventions to improve both depression and survival in patients with CHD.

Official Title

Fatigue, Anhedonia and Cardiac Prognostic Markers in Depressed Patients With Coronary Heart Disease

Quick Facts

Study Start:2020-12-01
Study Completion:2025-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04682769

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients seen at the Washington University Medical Center with coronary heart disease (CHD) documented by coronary angiography or history of acute coronary syndrome (ACS).
  2. * On a stable medication regimen (only minor changes in drug or dosage in last 30 days) are eligible for recruitment.
  3. * Meet the diagnostic criteria for a depressive disorder, score ≥ 14 on the Beck Depression Inventory (BDI-II), and not meet any exclusion criteria.
  1. * Thyroid disease or thyroid medications.
  2. * Moderate to severe cognitive impairment.
  3. * Major psychiatric comorbidities.
  4. * Taking antidepressants other than a selective serotonin reuptake inhibitor (SSRI).
  5. * Suicidal features.
  6. * Current substance abuse.
  7. * New York Heart Association (NYHA) class III or higher or a recent (\<3 months) acute coronary syndrome (ACS), coronary artery bypass graft surgery, cardiac hospitalization, or cardiac-related emergency department visit.
  8. * Advanced malignancy, a disability that would prevent compliance with the study protocol, or physician or patient refusal.

Contacts and Locations

Principal Investigator

Kenneth E Freedland, PhD
PRINCIPAL_INVESTIGATOR
Washington University School of Medicine

Study Locations (Sites)

Washington University
St Louis, Missouri, 63108
United States

Collaborators and Investigators

Sponsor: Washington University School of Medicine

  • Kenneth E Freedland, PhD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-12-01
Study Completion Date2025-05-31

Study Record Updates

Study Start Date2020-12-01
Study Completion Date2025-05-31

Terms related to this study

Additional Relevant MeSH Terms

  • Coronary Heart Disease
  • Depression